MAR 30, 2016 8:43 AM PDT

Recruiting Plant Peptides to Treat Multiple Sclerosis

WRITTEN BY: Kara Marker
Multiple Sclerosis (MS) is an autoimmune disease characterized by chronic inflammation, a result from an overexcited, misdirected immune response. A synthesized plant polypeptide called cyclotide is found in a variety of common plants, and it has the capability to reduce MS-related inflammation to the point where the disease can be curbed at a very early stage.
 

 MS is currently incurable, with available treatments to reduce the rate of progression including harsh side effects. The overactive inflammatory response causing MS stems from the destruction of myelin sheaths, the components of the nervous system that insulate nerve fibers. The current study indicating the future use of cyclotides as a more effective treatment was completed at the Medical University of Vienna and recently published in the journal PNAS.
 
“This could slow down the course of the disease in general,” said Christian Gruber, PhD, Chief Researcher at the Center for Physiology and Pharmacology at the university, said about the clinical sue of cyclotides.
 
In an animal model of MS, the research time orally administrated cyclotides and saw reduced symptoms of MS to the point where the most successful case showed no further progression of MS clinical signs. These preliminary studies mean that as soon as people start to show functional neurological problems that are characteristic of MS and receive a confirmative diagnose of MS via magnetic resonance imaging (MRI), the drug could be administered to prevent any further progression of the disease.
 
Cyclotides can be isolated from common plants like coffee, cucurbits, grass, and nightshade. It is highly advantageous that the drug develop from these macrocyclic peptides can be taken orally; most current treatments have to be administered intravenously.
 
By suppressing interleukin-2, an inflammatory cytokine that promotes the division of T lymphocytes, cyclotides reduce inflammation in patients with MS. When a reasonable cause instigates interleukin-2 production and activation of T lymphocytes, this is a protective pathway for the body. However, cases of MS are characterized by an inappropriate release of interleukin-2, leading to unnecessary inflammation, so suppressing the cytokine will successful reduce the severity of MS.
 
Additionally, cyclotide-based drugs have the potential to treat other autoimmune diseases characterized by an “overactive, misdirected immune response.”
 
Researchers from the Medical University of Vienna have authorized further development to be carried out at a pharmaceutical company called Cyxone.  A clinical trial testing the drug could begin as early as the end of 2018. More than 2.5 million people worldwide are affected by MS, and cyclotide-based drugs could be the first medication to truly make a difference in their lives.
 
 
Source:  Medical University of Vienna
 
About the Author
  • I am a scientific journalist and enthusiast, especially in the realm of biomedicine. I am passionate about conveying the truth in scientific phenomena and subsequently improving health and public awareness. Sometimes scientific research needs a translator to effectively communicate the scientific jargon present in significant findings. I plan to be that translating communicator, and I hope to decrease the spread of misrepresented scientific phenomena! Check out my science blog: ScienceKara.com.
You May Also Like
OCT 03, 2021
Cell & Molecular Biology
A Tumor-Suppressor Gene Plays a Role in the Circadian Rhythm
OCT 03, 2021
A Tumor-Suppressor Gene Plays a Role in the Circadian Rhythm
Organisms follow the cycle of the day, even at the cellular level, creating an internal clock. Humans' biology will ...
OCT 12, 2021
Immunology
Major Landmark in a 100-Year Search for a Malaria Vaccine
OCT 12, 2021
Major Landmark in a 100-Year Search for a Malaria Vaccine
In one of the greatest global health milestones of our time, the World Health Organization has approved the widespread d ...
OCT 11, 2021
Genetics & Genomics
A Genetic Risk Factor is Shared by Alzheimer's and Severe COVID-19
OCT 11, 2021
A Genetic Risk Factor is Shared by Alzheimer's and Severe COVID-19
While amyloid plaques are a hallmark of Alzheimer's disease, the neurological disorder has also been linked to inflammat ...
OCT 12, 2021
Health & Medicine
Atopic Dermatitis: A Harbinger of Autoimmune Diseases?
OCT 12, 2021
Atopic Dermatitis: A Harbinger of Autoimmune Diseases?
New research published in Allergy, Asthma & Clinical Immunology found an increased risk of autoimmune disease develo ...
OCT 16, 2021
Cell & Molecular Biology
Microtubules Found to Act as Mechanosensors
OCT 16, 2021
Microtubules Found to Act as Mechanosensors
As organisms grow, live, and move through the world, they're subjected to an array of internal and external forces. Biol ...
OCT 20, 2021
Genetics & Genomics
A New Approach in Glaucoma Treatment
OCT 20, 2021
A New Approach in Glaucoma Treatment
In the human eye, a space called the anterior chamber sits in between the cornea, which is a clear layer in the front of ...
Loading Comments...